Frontotemporal Dementia (FTD) Mechanistic Pathway describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders. [1]
Frontotemporal dementia (FTD) represents a group of progressive neurodegenerative disorders characterized by selective atrophy of the frontal and temporal lobes. FTD is the most common cause of young-onset dementia, accounting for 10-20% of all dementia cases with onset before age 65. The disease encompasses several clinical variants with distinct pathological substrates, including behavioral variant FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), non-fluent variant primary progressive aphasia (nvPPA), and corticobasal syndrome (CBS). Understanding the mechanistic pathways underlying FTD is essential for developing disease-modifying therapies. [2]
The behavioral variant represents the most common FTD subtype, comprising approximately 60% of cases. bvFTD is characterized by progressive changes in personality, behavior, and executive function. Core diagnostic features include disinhibition, apathy, loss of empathy, perseverative behaviors, and executive dysfunction. Patients often present with socially inappropriate behaviors, impulsivity, and neglect of personal hygiene. The disease typically progresses to profound dementia within 6-12 years of onset. Neuroanatomically, bvFTD shows preferential atrophy of the ventromedial prefrontal cortex, anterior cingulate cortex, and orbital frontal regions. [3]
svPPA presents with progressive loss of word meaning and object knowledge. Patients develop anomia, surface dyslexia, and loss of semantic knowledge for objects and faces. Behavioral features including compulsions and dietary changes may accompany the language deficits. The semantic deficit is characterized by progressive fluent aphasia with preserved speech fluency and grammar. Neuropathology typically shows FTLD-TDP type C pathology with severe temporal pole atrophy, particularly affecting the anterior inferior temporal gyrus. [4]
nvPPA presents with effortful, non-fluent speech and agrammatism. Patients demonstrate phonemic paraphasias, speech apraxia, and agrammatic sentence production. Comprehension remains relatively preserved in early stages. Motor features including parkinsonism and alien limb may develop in later stages. The pathology is typically FTLD-TDP type A with left frontal and perisylvian involvement. [5]
CBS presents with asymmetric motor features including apraxia, cortical sensory loss, alien limb phenomenon, and executive dysfunction. Cognitive deficits include frontotemporal dysfunction with prominent visuospatial and language deficits. The syndrome results from various underlying pathologies including corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and FTD with TDP-43 pathology. [6]
FTLD with TDP-43 pathology accounts for approximately 45% of FTD cases. The classification system divides FTLD-TDP into four types based on the distribution and morphology of inclusions: [7]
Tauopathies account for approximately 40% of FTD cases. The primary FTLD-tau subtypes include: [8]
FUS (Fused in Sarcoma) pathology accounts for approximately 10% of FTD cases. FTLD-FUS is characterized by: [9]
This subtype is associated with aggressive, early-onset presentations. [10]
Several genes cause autosomal dominant FTD: [11]
MAPT mutations on chromosome 17q21 cause familial FTD with tau pathology. Over 100 pathogenic variants have been identified, including P301L, P301S, and R406W. Mutations affect tau splicing, function, and aggregation propensity. The disease shows incomplete penetrance with variable expressivity. Typical onset occurs between 45-65 years. [12]
GRN mutations cause FTLD-TDP type A pathology. haploinsufficiency leads to reduced progranulin levels. Over 70 pathogenic variants have been identified, including nonsense and splice-site mutations. The disease shows complete penetrance by age 70. Female predominance has been reported in some families. Progranulin is involved in lysosomal function, wound healing, and inflammation. [7:1]
The hexanucleotide repeat expansion on chromosome 9p21 is the most common genetic cause of FTD and ALS. Normal alleles contain up to 30 repeats, while pathogenic expansions exceed 30 repeats, with some patients having thousands of repeats. The expansion leads to toxic gain-of-function through:
Genome-wide association studies have identified several FTD risk genes:
FTD involves accumulation of abnormal protein inclusions:
Tau is a microtubule-associated protein that stabilizes neuronal axons. In FTD, tau undergoes:
Tau aggregation disrupts axonal transport, causes synaptic dysfunction, and leads to neuronal death.
TDP-43 is an RNA-binding protein that regulates RNA splicing, stability, and transport. In FTD, TDP-43 undergoes:
TDP-43 pathology disrupts RNA metabolism, causes nucleocytoplasmic transport defects, and leads to synaptic dysfunction.
FTD involves global disruption of RNA processing:
Neuroinflammation is a consistent feature:
Neuroinflammation both results from and contributes to neurodegeneration.
Mitochondria are affected in FTD:
Synaptic deficits occur early in FTD pathogenesis. Loss of synaptic proteins reduces synaptic integrity. Reduced spine density impairs excitatory neurotransmission. Impaired neurotransmitter release affects synaptic plasticity. Disrupted functional connectivity between brain regions emerges. Network hypersynchrony reflects compensatory mechanisms. Synaptic failure precedes overt neuronal death.
FTD shows characteristic patterns of regional atrophy. bvFTD demonstrates ventromedial prefrontal, anterior cingulate, and orbital frontal involvement. svPPA shows anterior temporal pole and amygdala atrophy. nvPPA features left posterior frontal and insular cortex involvement. CBS exhibits asymmetric parietal-frontal cortex degeneration. The specific pattern correlates with clinical presentation.
Certain neuronal populations are selectively vulnerable in FTD. Von Economo neurons in frontal cortex show early vulnerability. Large pyramidal neurons in layer V undergo degeneration. GABAergic interneurons are affected, contributing to network dysfunction. Upper motor neurons degenerate in FTD-ALS overlap cases. Selective vulnerability determines clinical phenotype.
FTD pathology spreads through neural networks in predictable patterns. Prion-like spreading of misfolded proteins occurs trans-synaptically. Synaptic connectivity-based propagation follows functional networks. Transneuronal spread distributes pathology across connected regions. Network vulnerability determines progression patterns over time.
MRI reveals characteristic patterns of regional brain atrophy in FTD. Structural imaging shows frontal and temporal lobe volume loss. FDG-PET demonstrates hypometabolism corresponding to affected regions. Diffusion tensor imaging reveals white matter tract damage and disconnection. Tau PET helps exclude AD comorbidity in ambiguous cases. Advanced techniques including volumetric MRI quantify degeneration.
Multiple fluid biomarkers are under investigation for FTD. Neurofilament light chain (NfL) is elevated in CSF and plasma, reflecting neuronal injury. Total tau increases in neurodegeneration, though less specifically than in AD. YKL-40 serves as a marker of microglial activation. Progranulin levels are reduced in GRN mutation carriers. Combinations of biomarkers improve diagnostic accuracy.
Genetic testing identifies pathogenic variants in affected families. MAPT sequencing detects tau gene mutations causing FTLD-tau. GRN sequencing identifies progranulin mutations causing FTLD-TDP. C9orf72 repeat analysis quantifies hexanucleotide expansions. Panel testing provides comprehensive assessment of FTD genes. Pre-symptomatic testing is available for at-risk family members with appropriate counseling.
Comprehensive evaluation includes detailed history and neurological examination. Neuropsychological testing quantifies cognitive deficits across domains. MRI neuroimaging reveals characteristic atrophy patterns. FDG-PET demonstrates hypometabolism in affected regions. Genetic testing identifies familial variants when indicated. CSF analysis evaluates biomarkers including NfL and tau.
Current treatments focus on managing symptoms effectively. SSRIs effectively treat disinhibition, compulsions, and depressive symptoms. Low-dose antipsychotics manage severe behavioral disturbances with careful monitoring. Cholinesterase inhibitors show limited but sometimes beneficial effects. Memantine provides modest benefits for cognitive symptoms. Speech therapy helps language variants maintain communication abilities. Physical therapy addresses motor symptoms and maintains function. Occupational therapy supports daily living activities and independence.
Multiple tau-targeted approaches are in various stages of development. Aggregation inhibitors including methylene blue reduce pathological tau polymerization. Kinase inhibitors targeting GSK3β and CDK5 reduce abnormal tau phosphorylation. Active immunization with tau peptides shows promise in clinical trials. Passive immunotherapy with anti-tau antibodies is under active investigation. Microtubule stabilizers preserve neuronal connectivity and function.
TDP-43-targeted therapies are advancing rapidly toward clinical application. ASO therapy targeting TARDBP reduces toxic protein levels. Splicing modulators correct pathological cryptic exon inclusion. Aggregation inhibitors prevent pathological protein polymerization. Gene editing approaches using CRISPR technology offer precise treatment potential. RNA-based therapeutics provide alternative strategies for intervention.
Targeting neuroinflammation shows significant therapeutic potential. CSF1R antagonists reduce harmful microglial populations. TREM2 modulators enhance beneficial microglial functions. Anti-inflammatory approaches including NSAIDs are being investigated in trials. Minocycline and small molecules reduce microglial activation. Modulating the peripheral immune response offers additional opportunity.
Cell-based and regenerative strategies are emerging for FTD. Stem cell transplantation provides cellular replacement potential. Gene therapy delivers therapeutic constructs via AAV vectors. RNA-based therapeutics enable precise protein modulation. Combination approaches targeting multiple mechanisms may prove most effective for disease modification.
The triggers of protein aggregation remain incompletely understood. What initiates the first misfolding event in susceptible neurons remains unknown. Why specific brain regions show selective vulnerability is unclear. What determines clinical subtype among FTD variants requires investigation. How genetic factors interact with environmental triggers is actively being explored. Understanding initiation is critical for developing prevention strategies.
Better biomarkers are needed for improved clinical practice. Early detection before clinical symptoms would enable preventive interventions. Disease progression monitoring requires validated markers for clinical trials. Therapeutic response markers would accelerate drug development. Biomarkers for specific pathology types would improve diagnostic accuracy. Multi-modal biomarker approaches show the most promise.
Key therapeutic targets span multiple biological pathways. Protein aggregation initiation and propagation are critical targets. Spread of pathology between neurons requires intervention. Neuroinflammation modulation offers therapeutic opportunity. Synaptic dysfunction restoration may improve function. Combinations targeting multiple mechanisms may prove most effective for disease modification.
FTD represents a significant and underappreciated health burden. Prevalence is approximately 15 per 100,000 in those under age 65. Incidence is approximately 3-4 per 100,000 person-years. Peak onset occurs between ages 45-65, affecting prime working years. Both sporadic and familial forms exist in the population. Approximately 40% of cases have some family history of disease.
FTD creates substantial economic burden for society. Direct medical costs include diagnostics, medications, and clinical care. Lost productivity affects both patients and caregivers substantially. Long-term care needs increase dramatically as disease progresses. Caregiver burden is significant and often underappreciated by healthcare systems. Young-onset dementia particularly affects working-age individuals and families.
FTD caregivers face unique and demanding challenges. Behavioral changes are difficult to manage on a daily basis. Young-onset affects family finances and retirement planning significantly. Progressive decline eventually leads to complete dependency for care. Caregiver burnout is common and often underrecognized clinically. Support programs improve outcomes for both patients and family caregivers.
Precision medicine approaches are advancing rapidly for FTD. Genetic subtypes inform therapeutic selection for individual patients. Pathology-specific biomarkers guide treatment choice and development. Individualized approaches based on genetic background are becoming reality. Combination therapies targeting multiple mechanisms are under active development.
Integrative multi-omics approaches are transforming FTD research. Genomics identifies causal variants and risk factors in affected families. Transcriptomics reveals gene expression changes in affected tissues. Proteomics characterizes protein alterations in disease states. Metabolomics uncovers metabolic perturbations contributing to neurodegeneration. Systems biology integrates findings for comprehensive understanding of disease mechanisms.
AI and machine learning are being applied to FTD research and care. Image analysis algorithms improve diagnostic accuracy and progression tracking. Predictive models identify at-risk individuals before symptom onset. Drug discovery platforms accelerate therapeutic development. Natural language processing extracts knowledge from scientific literature. Deep learning approaches analyze neuroimaging data. Computer vision automates pathological assessment.
The autophagy-lysosome system is impaired in FTD. Lysosomal dysfunction accumulates within neurons. Autophagic flux reductions impair protein clearance. Lysosomal membrane permeability releases hydrolases. Cathepsin activation contributes to cell death. Autophagy receptor proteins are sequestered in inclusions. mTORC1 hyperactivation inhibits autophagy initiation. TFEB nuclear translocation is reduced. Enhancing autophagy may provide therapeutic benefit.
Endoplasmic reticulum stress is prominent in FTD. The unfolded protein response is chronically activated. PERK-eIF2α axis drives pro-apoptotic signaling. CHOP expression promotes cell death. ER calcium homeostasis is disrupted. Mitochondrial calcium transfer is impaired. ER-mitochondria contact sites are altered. Reducing ER stress represents a therapeutic target.
Metal ion regulation is disturbed in FTD. Iron accumulation occurs in affected regions. Copper metabolism is altered in specific subtypes. Zinc homeostasis is disrupted. Manganese deposition occurs in some cases. Metal chelation approaches are under investigation. Metal-binding proteins show altered expression. Oxidative stress results from metal dysregulation.
The neuronal cytoskeleton is affected in FTD. Microtubule stability is compromised. Actin dynamics are altered. Intermediate filament accumulation occurs. Axonal transport is impaired. Motor protein function is reduced. Cytoskeletal stabilizers are being investigated. Dynactin mutations affect axonal transport.
The default mode network is disrupted in FTD. Functional connectivity between posterior and anterior regions declines. Self-referential processing is impaired. Mind-wandering is altered in bvFTD. Network metrics predict disease progression. DMN connectivity correlates with behavioral symptoms. Resting-state networks show characteristic patterns. Targeting network dysfunction may provide therapy.
The salience network is hyperactive in bvFTD. Anterior insula shows increased activation. Responses to salient stimuli are abnormal. Network hyperactivity correlates with disinhibition. The salience network interacts with DMN. GABAergic dysfunction contributes to network changes. Transcranial magnetic stimulation targets salience regions.
Executive control networks are impaired in FTD. Dorsolateral prefrontal cortex shows reduced activity. Cognitive flexibility is compromised. Goal-directed behavior is disrupted. Network connectivity predicts executive function. Transcranial stimulation may enhance function. Rehabilitation approaches target network deficits.
FTD shows sex-specific features. Women may be disproportionately affected in some subtypes. Disease progression differs by sex. Hormonal factors may influence risk. Sex-specific biomarkers are being investigated. Treatment responses may vary by sex. Understanding sex differences improves care.
Age significantly affects FTD presentation. Early-onset cases show more rapid progression. Late-onset cases often have less genetic basis. Age influences pathological subtype distribution. Comorbid pathologies increase with age. Age-specific biomarkers are being developed. Management approaches differ by age.
AD comorbidity is common in FTD cases. Mixed pathology affects clinical presentation. Biomarkers help identify comorbidity. Treatment approaches must address both pathologies. Tau PET positivity indicates comorbid AD. Amyloid accumulation occurs in a subset. Detection of comorbidity improves management.
Lewy body pathology sometimes co-occurs with FTD. DLB features may be present. Fluctuating cognition occurs with FTD. Visual hallucinations may develop. Autonomic dysfunction is more severe. Treatment must consider both pathologies. Biomarkers distinguish pure FTD from DLB overlap.
Vascular lesions contribute to FTD phenotypes. Small vessel disease worsens cognitive outcomes. White matter hyperintensities are common. Vascular risk factors affect progression. Treating vascular disease may improve outcomes. Combined approaches address multiple mechanisms.
Progressive functional decline characterizes FTD. Activities of daily living become impaired. Instrumental ADLs are affected early. Mobility declines in later stages. Nursing home placement often becomes necessary. Palliative care improves quality of life. Advance care planning is essential.
Behavioral disturbances significantly impact quality of life. Agitation and aggression are challenging. Sleep disturbances are common. Apathy limits patient engagement. Caregiver stress correlates with behaviors. Non-pharmacological approaches are first-line. Medications may be necessary in some cases.
Robust support systems improve outcomes. Multidisciplinary care teams provide comprehensive support. Caregiver education improves care quality. Support groups provide emotional support. Telehealth options expand access to care. Research participation offers hope and access to new treatments.
Frontotemporal dementia encompasses a heterogeneous group of disorders unified by selective frontal and temporal lobe degeneration. The major pathological subtypes involve tau, TDP-43, and FUS proteinopathies, each with distinct genetic and molecular mechanisms. Understanding these pathways provides opportunities for developing targeted therapies. While current treatments remain symptomatic, disease-modifying approaches targeting protein aggregation, RNA metabolism, and neuroinflammation offer hope for future interventions. Research advances in genetics, biomarkers, and therapeutics are transforming the field and providing new avenues for treating this devastating group of disorders.
The behavioral variant is the most common FTD subtype, comprising approximately 60% of cases. Core diagnostic features include progressive deterioration of social conduct and executive abilities, with relative preservation of memory and visuospatial function [2].
Early symptoms (within 3 years of onset):
Later progression:
The diagnosis of bvFTD requires presence of at least three of six core criteria, with progressive deterioration affecting daily function.
PPA manifests as progressive language impairment as the initial and predominant symptom, with other cognitive domains relatively preserved for at least 2 years. Three subtypes are recognized:
Nonfluent/agrammatic variant (nfvPPA):
Semantic variant (svPPA):
Logopenic variant (lvPPA):
FTD frequently overlaps with movement disorders:
Cortico-basal syndrome (CBS): Presents with asymmetric rigidity, dystonia, myoclonus, and apraxia, often with cortical sensory loss. Pathologically, CBS is associated with tau pathology (4R-tau) in most cases [3].
Progressive supranuclear palsy (PSP): Characterized by vertical gaze palsy, early postural instability with falls, axial rigidity, and bradykinesia. PSP pathology involves accumulation of tau-containing neurofibrillary tangles, glial lesions (tufted astrocytes), and coiled bodies [4].
FTD with motor neuron disease: The association between FTD and ALS is well-recognized, with approximately 15% of FTD patients showing clinical or electrophysiological evidence of motor neuron disease, and conversely, up to 50% of ALS patients show FTD-like cognitive changes.
Approximately 30-40% of FTD cases have a family history consistent with autosomal dominant inheritance, with three major genes accounting for the majority of familial cases:
C9orf72 hexanucleotide repeat expansion
The most common genetic cause of familial FTD and ALS, found in approximately 25% of familial FTD and 40% of familial ALS cases [5]. The pathogenic mechanism involves:
The clinical phenotype is variable, ranging from pure bvFTD to ALS-FTD. Anticipatory anticipation is observed, with earlier onset in subsequent generations.
GRN (Progranulin) mutations
Granulin gene mutations cause approximately 5-10% of familial FTD and 1-2% of sporadic FTD [6]. Over 70 pathogenic GRN mutations have been identified, including nonsense, frameshift, and splice-site mutations that cause haploinsufficiency.
MAPT (Tau) mutations
The tau gene on chromosome 17q21.31 encodes the microtubule-associated protein tau. Over 50 pathogenic MAPT mutations cause familial FTD, all resulting in tau dysfunction [7]:
Additional genes modify FTD risk or influence phenotype:
TMEM106B: Polymorphisms in this lysosomal protein gene modify risk for FTD-TDP, particularly in carriers of GRN or C9orf72 mutations [8].
TBK1: TANK-binding kinase 1 mutations cause rare FTD-ALS cases.
CHCHD10: Mitochondrial protein mutations cause ALS-FTD with mitochondrial dysfunction.
ALSgenes database: Lists over 25 genes associated with ALS-FTD spectrum.
Tau pathology in FTD takes multiple forms depending on the underlying cause:
3R-tauopathies:
4R-tauopathies:
3R+4R tauopathies:
TDP-43 pathology occurs in approximately 50% of FTD cases, classified into distinct subtypes:
FTD-TDP type A: Numerous compact neuronal cytoplasmic inclusions and short neurites; associated with GRN mutations.
FTD-TDP type B: Moderate numbers of neuronal cytoplasmic inclusions without neurites; associated with C9orf72 expansions.
FTD-TDP type C: Long neurites with little neuronal cytoplasmic inclusions; associated with svPPA.
FTD-TDP type D: Prominent neuronal intranuclear inclusions; associated with valosin-containing protein (VCP) mutations [9].
Fused in sarcoma (FUS) pathology accounts for approximately 10% of FTD cases:
The formation of insoluble protein inclusions is a hallmark of FTD, but the relationship between inclusions and neuronal dysfunction is complex:
Gain-of-function toxicity: Aggregated proteins may acquire toxic properties, disrupting cellular homeostasis.
Loss-of-function: Sequestration of normal protein into inclusions may deplete functional pools.
Seeding and propagation: Pathological proteins may template misfolding of native proteins, spreading pathology across brain networks.
FTD proteins (TDP-43, FUS) are RNA-binding proteins with nuclear functions:
Splicing disruption: TDP-43 regulates alternative splicing; loss of nuclear function causes aberrant splicing patterns.
RNA transport deficits: TDP-43 and FUS are involved in mRNA transport to dendritic and axonal compartments.
Stress granule formation: Under cellular stress, these proteins form stress granules that may become pathological if they persist [10].
Multiple lines of evidence connect FTD to mitochondrial impairment:
Energy failure: Neuronal activity requires substantial ATP, which is compromised by mitochondrial dysfunction.
Calcium dysregulation: Mitochondrial calcium handling is impaired, affecting synaptic function and survival.
Reactive oxygen species: Mitochondrial dysfunction increases ROS production, causing oxidative damage.
Mitophagy defects: Impaired clearance of damaged mitochondria leads to accumulation of dysfunctional organelles.
Microglial activation is a consistent finding in FTD:
Imaging studies: PET ligands for TSPO (translocator protein) show increased microglial activation in FTD brains.
Genetic evidence: GWAS have identified immune-related genes as FTD risk factors.
Bidirectional relationship: Neuroinflammation contributes to neurodegeneration, and neuronal dysfunction may activate microglia.
Early synaptic loss is a key contributor to cognitive decline:
Postsynaptic deficits: Altered glutamate receptor trafficking and signaling.
Presynaptic dysfunction: Impaired neurotransmitter release and vesicle recycling.
Synaptic proteins: Direct interaction of FTD proteins with synaptic machinery.
Neuropsychological testing: Quantifies deficits in executive function, language, behavior, and social cognition.
Neurological examination: Documents motor signs, reflexes, and coordination.
Behavioral assessment: Quantifies behavioral disturbances using standardized instruments.
Structural MRI: Shows characteristic patterns of atrophy:
FDG-PET: Shows hypometabolism in similar regions, often before atrophy is visible.
Tau PET: Useful when Alzheimer pathology is in the differential, but currently limited for FTD-specific tauopathies.
Molecular PET: No specific TDP-43 or FUS ligands currently available.
Cerebrospinal fluid:
Blood:
Genetic testing: Recommended for patients with family history or early onset.
Behavioral management: Environmental modifications, caregiver education, and behavioral interventions.
Pharmacological:
Gene-specific strategies:
Aggregation inhibitors:
Modulation of proteostasis:
Anti-inflammatory approaches:
Speech and language therapy: Maximizes communication abilities in PPA variants.
Physical therapy: Maintains mobility and prevents complications.
Nutritional support: Addresses weight loss and dysphagia.
Caregiver support: Essential given the behavioral challenges and long disease duration.
Multiple models recapitulate aspects of FTD:
Patient-derived iPSCs enable study of human neurons:
FTD spreads along brain networks:
Default mode network and executive networks show early dysfunction:
Early differentiation between FTD and AD is clinically important but can be challenging:
Cognitive profiles:
Neuroimaging:
CSF biomarkers:
bvFTD vs. psychiatric disorders:
PPA vs. stroke:
Fluid biomarkers:
Imaging advances:
Environmental modifications:
Caregiver strategies:
Disinhibition and agitation:
Apathy:
Language deficits:
Parkinsonism:
Motor neuron disease:
bvFTD:
PPA variants:
FTD-ALS:
Positive prognostic factors:
Negative prognostic factors:
Prevalence:
Economic burden:
Behavioral symptoms:
Cognitive demands:
Emotional burden:
Imaging biomarkers:
Fluid biomarkers:
Disease-modifying approaches:
Neuroprotective strategies:
Outcome measures:
Trial populations:
Boutoleau-Bretonniere et al. Neuroinflammation in FTD (2015). 2015. ↩︎
Chen-Plotkin et al. FTD biomarkers (2014). 2014. ↩︎
Lashley et al. FTD neuropathology (2015). 2015. ↩︎
Piguet et al. FTD clinical features (2013). 2013. ↩︎
Seelaar et al. FTD epidemiology (2011). 2011. ↩︎
Boxer et al. Clinical trials in FTD (2019). 2019. ↩︎
Perneczky et al. Progranulin and FTD (2018). 2018. ↩︎ ↩︎
Greaves et al. C9orf72 repeat expansion (2019). 2019. ↩︎
Wojtas et al. FTD with TDP-43 (2020). 2020. ↩︎
Gao et al. Tau propagation (2021). 2021. ↩︎
Cruts et al. Molecular genetics of FTD (2013). 2013. ↩︎
Rohrer et al. FTD genetics (2015). 2015. ↩︎